Literature DB >> 25189380

Comparative secretome analysis of cholangiocarcinoma cell line in three-dimensional culture.

Phanthakarn Tit-Oon1, Daranee Chokchaichamnankit2, Amnart Khongmanee1, Phannee Sawangareetrakul2, Jisnuson Svasti1, Chantragan Srisomsap2.   

Abstract

Cholangiocarcinoma (CCA) is a lethal malignancy which occurs with relatively high incidence in Thailand. This cancer is often difficult to diagnose and associated with high mortality. The secretome, containing the secreted proteins from cells, are potentially useful as biomarkers of cancers. Since three-dimensional (3D) cell culture may mimic growth characteristics and microenvironment of solid tumors in vivo better than monolayer culture, we have developed culture of CCA in natural collagen-based scaffold, to enable analysis of the secretome by 2DE. Our results indicated that CCA growth in 3D environment alters cell shape significantly and enhances extracellular matrix deposition. Interestingly, more secreted proteins were detected from 3D culture compared to monolayer culture. Secretome analysis using 2DE coupled with LC-MS/MS demonstrated 10 secreted proteins uniquely found in 3D culture. Moreover, 25 proteins were enriched in 3D culture compared to monolayer culture, including 14-3-3 σ, triosephosphate isomerase, phosphoglycerate mutase 1, α-enolase, and L-plastin. Immunoblotting was used to confirm the presence of L-plastin in conditioned media of CCA and of hepatocellular carcinoma (HCC) cell lines. The results revealed that L-plastin, an actin bundling protein, was uniquely expressed only in the CCA cell line and could be a promising biomarker for differential diagnosis of CCA compared to HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25189380     DOI: 10.3892/ijo.2014.2636

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma.

Authors:  Onanong Buhome; Molin Wongwattanakul; Jureerut Daduang; Temduang Limpaiboon
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

2.  Investigation of Brain Function-Related Myokine Secretion by Using Contractile 3D-Engineered Muscle.

Authors:  Takeshi Sugimoto; Tomohiro Nakamura; Sho Yokoyama; Toshia Fujisato; Satoshi Konishi; Takeshi Hashimoto
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

3.  Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.

Authors:  Gyem Tshering; Palden Wangyel Dorji; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

4.  Biomechanical, ultrastructural, and electrophysiological characterization of the non-human primate experimental glaucoma model.

Authors:  VijayKrishna Raghunathan; J Seth Eaton; Brian J Christian; Joshua T Morgan; James N Ver Hoeve; Chen-Yuan Charlie Yang; Haiyan Gong; Carol A Rasmussen; Paul E Miller; Paul Russell; T Michael Nork; Christopher J Murphy
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

5.  Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma.

Authors:  Mohammad Zahid Mustafa; Viet Hung Nguyen; François Le Naour; Eleonora De Martin; Elvire Beleoken; Catherine Guettier; Catherine Johanet; Didier Samuel; Jean-Charles Duclos-Vallee; Eric Ballot
Journal:  J Transl Med       Date:  2016-01-16       Impact factor: 5.531

6.  Evidence for acute contraction-induced myokine secretion by C2C12 myotubes.

Authors:  Yasuro Furuichi; Yasuko Manabe; Mayumi Takagi; Miho Aoki; Nobuharu L Fujii
Journal:  PLoS One       Date:  2018-10-24       Impact factor: 3.240

7.  Quantitative proteomic analysis of the association between decreasing O‑GlcNAcylation and metastasis in MCF‑7 breast cancer cells.

Authors:  Pukkavadee Netsirisawan; Daranee Chokchaichamnankit; Kittirat Saharat; Chantragan Srisomsap; Jisnuson Svasti; Voraratt Champattanachai
Journal:  Int J Oncol       Date:  2020-03-20       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.